## Contents

### Highlights of This Issue  5831

### SPECIAL FEATURES

#### Editorial

5833  
**Gauging Progress in a Decades-Old Fight**  
Jesse Potash and Kenneth C. Anderson

#### CCR Translations

5834  
**Model T Muscle CARs Can Treat Brain Tumors**  
Laura A. Johnson  
*See article p. 5949*

#### CCR New Strategies

5837  
**New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents**  
Katherine A. Janeway and Robert G. Maki

#### CCR Perspectives in Drug Approval

5845  
**U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma**  

#### Molecular Pathways

5850  
**Molecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene **CPT1C** to Promote Survival**  
Patrick T. Reilly and Tak W. Mak

### Review

5856  
**The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer**  
Brian M. Slomovitz and Robert L. Coleman

### HUMAN CANCER BIOLOGY

5865  
**Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis**  
Carolyn D. Hurst, Fiona M. Platt, Claire F. Taylor, and Margaret A. Knowles

5878  
**Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas**  

5888  
**Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells**  
Shahriar Koochekpour, Sunipa Majumdar, Gissou Azadhabari, Kristopher Atwood, Ray Scioneaux, Dhatchayani Subramani, Charles Manhardt, Giovanni D. Lorusso, Stacey S. Willard, Hillary Thompson, Mogian Shourideh, Katayoon Rezaei, Oliver Sartor, James L. Mohler, and Robert L. Vessella

5902  
**Expression of Serotonin Receptors in Human Hepatocellular Cancer**  
Christopher Soll, Marc-Oliver Rieener, Christian Eugen Oberkofler, Claus Hellerbrand, Peter J. Wild, Michelle L. DeOliveira, and Pierre-Alain Clavien

---

The Journal of Clinical and Translational Research  iii  www.aacrjournals.org

Downloaded from clinanceres.aacrjournals.org on May 18, 2017. © 2012 American Association for Cancer Research.
CANCER THERAPY: PRECLINICAL

5911  Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo
Fiona Simpkins, Pedro Hevia-Paez, Jun Sun, Wendy Ullmer, Candace A. Gilbert, Thiago da Silva, Ali Pedram, Ellis R. Levin, Isuldinha M. Reis, Brian Rabinovich, Diana Azzam, Xiang-Xi Xu, Tan A. Ince, Ji-Yeon Yang, Roel G.W. Verhaak, Yiling Lu, Gordon B. Mills, and Joyce M. Slangerland

5924  Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status
Maria Joao Baptista, Ana Muntañola, Eva Calpe, Pau Abrissqeta, Olga Salamero, Eva Fernandez, Carles Codony, Eva Giné, Susana G. Kalko, Marta Crespo, and Francesc Bosch

5934  Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vitro Antitumor Activity
Seong-Hoon Yun, Eun-Seon Park, Sung-Won Shin, Yong-Woo Na, Jin-Yeong Han, Jin-Sook Jeong, Valeria V, Shastina, Valentin A. Stonik, Joo-In Park, and Jong-Young Kwak

5949  Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells
See commentary p. 5834

5961  FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51
Nu Zhang, Xinjian Wu, Lixuan Yang, Feizhe Xiao, Heng Zhang, Aidong Zhou, Zhengqong Huang, and Suyun Huang

IMAGING, DIAGNOSIS, PROGNOSIS

5972  Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer
Dharamna Madhavan, Manuela Zachn, Markus Wallwiener, Katarina Cuk, Caroline Modugno, Martina Scharpff, Sarah Schott, Jorg Heil, Andrea Turchinovich, Rongxi Yang, Axel Benner, Sabine Rietdorf, Andreas Trumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, and Barbara Burwinkel

5983  Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study
Xia Pu, Yuanqing Ye, Margaret R. Spitz, Liang Wang, Jian Gu, Scott M. Lippman, Michelle A.T. Hildebrandt, Wau Kihong, John D. Minna, Jack A. Roth, Ping Yang, and Xifeng Wu

5992  Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
Masanori Terashima, Koji Kitada, Atsushi Ochiai, Wataru Ichikawa, Issi Kurauchi, Shuntichi Sakuramoto, Hitsuhi Katai, Takeshi Sano, Hiroshi Imamura, and Mitsuuru Sasaki; for the ACTS-GC Group

6001  ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients
Anita Sveen, Trude H. Aagesen, Arild Nesbakken, Gunn Iren Meling, Torleiv O. Rognum, Knut Liestøl, Rolf I. Skotheim, and Ragnhild A. Lothe

CANCER THERAPY: CLINICAL

6011  A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Bulis, and Susan M. Blaney
### Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

### Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

### Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, and Priti S. Hegde

### Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, Lukas Bubendorf, Rolf Jaggii, Daniel C. Betticher, Peter Brauchli, Denise Cotting, Cornelia Droegge, Ralph Winterhalder, Daniele Siciliano, Dominik R. Berthold, Miklos Pless, Ralph Schiess, Roger von Moos, and Silke Gillessen; for the Swiss Group for Clinical Cancer Research (SAKK)

### Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Yael P. Mossé, Emily Lipsitz, Elizabeth Fox, David T. Teachey, John M. Maris, Brenda Weigel, Peter C. Adamson, Mark A. Ingle, Charlotte H. Ahern, and Susan M. Blaney

### Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine
Shigeyuki Matsui, Richard Simon, Pingping Qu, John D. Shaughnessy Jr, Bart Barlogie, and John Crowley

### Spleen Cells from Young Donors Eradicate Large Tumors—Letter
Laszlo Radvanyi

### Bioluminescence Imaging of Prenylation Inhibition—Letter
Philippe Clezardin

### Correction: The Use of Quantitative Real-Time Reverse-Transcriptase PCR for 5’ and 3’ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Kendall J. Blumer, Katherine Weilbaecher, and David Piwnica-Worms
Serotonin receptors are expressed in the liver and human hepatocellular cancer (HCC). The cover shows the immunohistochemical staining of the serotonin receptor 1B (HTR1B) in a specimen of human HCC. In a subset of tumors, the expression of HTR1B was significantly increased compared with corresponding nontumor liver tissue of the same patient. The expression of the receptor correlated with a higher proliferation rate and tumor size, suggesting an involvement of serotonin receptors in tumor growth of human HCC. For details, see the article by Soll and colleagues on page 5902 of this issue.